Published 21:44 IST, August 25th 2020

GeoVax biotechnology firm begins early-stage study of HIV combination therapy

GeoVax Labs a biotechnology company has initiated Phase 1 clinical study of combination therapy in HIV-positive patients utilizing GeoVax’s novel component

Reported by: Anmol Bali
Follow: Google News Icon
  • share
null | Image: self
Advertisement

GeoVax Labs a biotechlogy company has initiated Phase 1 clinical study of combination rapy in HIV-positive patients utilizing GeoVax’s vel boost component MVA62B. study is a collaboration of researchers led by Dr. Steven Deeks, Professor of Medicine at University of California San Francisco (UCSF) and a faculty member in Division of HIV, Infectious Diseases and Global Medicine at Zuckerberg San Francisco General Hospital. study is designed to induce remission in HIV-positive individuals, also kwn as a “functional cure.” It is being funded by Foundation for AIDS Research.

Re: COVID Delays 2020's Earth Overshoot Day By A Month Versus 2019; '1.6 Earths Needed'

Advertisement

single-arm, open-label study will enroll 20 HIV-infected ults who are on stable and effective antiretroviral rapy (ART). investigational regimen entails a combination of vaccinations (DNA priming and MVA boosting), ministration of broly neutralizing antibodies, and a Toll-like receptor 9 agonists. GeoVax is providing its vel boost component, MVA62B, for use in studies. MVA62B is boosting component for GeoVax’s preventive HIV vaccine, GOVX-B11, which has successfully completed a Phase 2 clinical trial.

Re US: Tortoise Named Solomon Returns Home After Being Missing For 74 Days

Advertisement

“This Phase 1 trial will be most comprehensive study to date to assess efficacy of synergistic approaches to control HIV infection,” said Dr. Steven Deeks.

Can produce both CD8+ and CD4+ T cells

Harriet Robinson, Ph.D., CSO Emeritus of GeoVax, commented, “We have previously demonstrated that our HIV vaccine can stimulate production of both CD8+ and CD4+ T cells in HIV-positive individuals, which is intended function of MVA62B vaccine in UCSF rapeutic study. Our vaccine also has a well-documented safety profile in more than 500 humans. We are hopeful that combination of techlogies in this study will yield a promising regimen to reduce latent HIV reservoirs and reby work towards a functional cure for HIV.”

Re: US Says Energy Firms Shut 57.6% Of Offshore Crude Oil Production Over Twin Storm Threat

Advertisement

Re: Ireland's 1st Hindu Temple Inaugurated In Country's Capital Dublin After Deces-long Wait

21:44 IST, August 25th 2020